Abstract

Since identification in 1994 of leptin, a hormone produced by adipocytes, adipose tissue has become the subject of intensive research. These studies contributed to the discovery that adipocytes have the ability to synthesize and secrete biologically active substances called „adipokines”. Adipokines include a variety of cytokines, peptide hormones and enzymes that play a role in a wide variety of biological functions. For example, they are involved in the regulation of appetite, energy homeostasis, vascular hemostasis, blood pressure, inflammatory and immune processes and play a role in the metabolism of carbohydrates and fats. In obese patients, the secretion of adipokines is frequently abnormal. These changes may predispose to the development of insulin resistance, hypertension and inflammation. Therefore, adipokines are the subject of ongoing clinical trials. The family of adipokines is increasing by the newly discovered peptides. This paper presents the current state of knowledge about retinol binding protein 4 (RBP-4), fasting-induced adipose factor/angiopoietin-like protein 4 (FIAF/ANGPTL4), fibroblast growth factor-21 (FGF21), dipeptidyl peptidase-4 (DPP-4), irisin and their potential role in the pathogenesis of metabolic disorders associated with obesity. The knowledge of the role of newly discovered adipokines may help in the treatment of metabolic syndrome.

References

• 1. Ali F.H., Ranneh Y.: Angiopoietin-like protein 4 and the level offree fatty acids in human blood plasma: is there a link? Med. Chem.,2013; 3: 276-281 2 Alkharfy K.M., Al-Daghri N.M., Vanhoutte P.M., KrishnaswamyS., Xu A.: Serum retinol-binding protein 4 as a marker for cardiovasculardisease in women. PLoS One, 2012; 7: e48612
  Google Scholar
• 2. diabetes. Cell Metab., 2013; 18: 333-340
  Google Scholar
• 3. Argyropoulos G., Harper M.E.: Uncoupling proteins and thermoregulation.J. Appl. Physiol., 2002; 92: 2187-2198 4 Bäckhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., SemenkovichC.F., Gordon J.I.: The gut microbiota as an environmentalfactor that regulates fat storage. Proc. Natl. Acad. Sci. USA, 2004;101: 15718-15723
  Google Scholar
• 4. contributes to insulin resistance in obesity and type 2 diabetes.Nature, 2005; 436: 356-362 81 Yoshida K., Shimizugawa T., Ono M., Furukawa H.: Angiopoietin–like protein 4 is a potent hyperlipidemia-inducing factor in miceand inhibitor of lipoprotein lipase. Lipid Res., 2002; 43: 1770-1772 82 Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., FriedmanJ.M.: Positional cloning of the mouse obese gene and its humanhomologue. Nature, 1994; 372: 425-432 83 Zhu P., Goh Y.Y., Chin H.F., Kersten S., Tan N.S.: Angiopoietin-like4: a decade of research. Biosci. Rep., 2012; 32: 211-219
  Google Scholar
• 5. Bajzová M., Kováciková M., Vítková M., Klimcáková E., Polák J., KovácováZ., Viguerie N., Vedral T., Mikulásek L., Srámková P., Srp A., HejnováJ., Langin D., Stich V.: Retinol-binding protein 4 expression in visceraland subcutaneous fat in human obesity. Physiol. Res., 2008; 57: 927-934
  Google Scholar
• 6. Balagopal P., Graham T.E., Kahn B.B., Altomare A., Funanage V.,George D.: Reduction of elevated serum retinol binding protein inobese children by lifestyle intervention: association with subclinicalinflammation. J. Clin. Endocrinol. Metab., 2007; 92: 1971-1974
  Google Scholar
• 7. Beenken A., Mohammadi M.: The FGF family: biology, pathophysiologyand therapy. Nat. Rev. Drug Discov., 2009; 8: 235-253
  Google Scholar
• 8. Blaut M., Klaus S.: Intestinal microbiota and obesity. Handb. Exp.Pharmacol., 2012; 209: 251-273
  Google Scholar
• 9. Bobbert T., Schwarz F., Fischer-Rosinsky A., Pfeiffer A.F., MöhligM., Mai K., Spranger J.: Fibroblast growth factor 21 predicts themetabolic syndrome and type 2 diabetes in Caucasians. DiabetesCare, 2013; 36: 145-149
  Google Scholar
• 10. Boström P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., RasbachK.A., Boström E.A., Choi J.H., Long J.Z., Kajimura S., ZingarettiM.C., Vind B.F., Tu H., Cinti S., Højlund K., Gygi S.P., Spiegelman B.M.:A PGC1-α-dependent myokine that drives brown-fat-like developmentof white fat and thermogenesis. Nature, 2012; 481: 463-468
  Google Scholar
• 11. Chen W.W., Li L., Yang G.Y., Li K., Qi X.Y., Zhu W., Tang Y., Liu H.,Boden G.: Circulating FGF-21 levels in normal subjects and in newlydiagnose patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol.Diabetes, 2008; 116: 65-68
  Google Scholar
• 12. Chiba M., Saitoh S., Ohnishi H., Akasaka H., Mitsumata K., FurukawaT., Shimamoto K.: Associations of metabolic factors, especiallyserum retinol-binding protein 4 (RBP4), with blood pressure in Japanese– the Tanno and Sobetsu study. Endocr. J., 2010; 57: 811-817
  Google Scholar
• 13. Choi Y.K, Kim M.K., Bae K.H., Seo H.A., Jeong J.Y., Lee W.K., KimJ.G., Lee I.K., Park K.G.: Serum irisin levels in new-onset type 2 diabetes.Diabetes Res. Clin. Pract., 2013; 100: 96-101
  Google Scholar
• 14. Fernández-Real J.M., Moreno J.M., Ricart W.: Circulating retinolbinding protein-4 concentration might reflect insulin resistanceassociatediron overload. Diabetes, 2008; 57: 1918-1925
  Google Scholar
• 15. Fleissner C.K., Huebel N., Abd El-Bary M.M., Loh G., Klaus S.,Blaut M.: Absence of intestinal microbiota does not protect micefrom diet-induced obesity. Br. J. Nutr., 2010; 104: 919-929
  Google Scholar
• 16. Friebe D., Neef M., Erbs S., Dittrich K., Kratzsch J., Kovacs P.,Blüher M., Kiess W., Körner A.: Retinol binding protein 4 (RBP4) isprimarily associated with adipose tissue mass in children. Int. J. Pediatr.Obes., 2011; 6: e345-e352
  Google Scholar
• 17. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L.,Kharitonenkov A., Bumol T., Schilske H.K., Moller D.E.: The effectsof LY2405319, an FGF21 analog, in obese human subjects with type
  Google Scholar
• 18. Galic S., Oakhill J.S., Steinberg G.R.: Adipose tissue as an endocrineorgan. Mol. Cell. Endocrinol., 2010; 316: 129-139
  Google Scholar
• 19. Gälman C., Lundåsen T., Kharitonenkov A., Bina H.A., ErikssonM., Hafström I., Dahlin M., Amark P., Angelin B., Rudling M.: The circulatingmetabolic regulator FGF21 is induced by prolonged fastingand PPARα activation in man. Cell Metab., 2008; 8: 169-174
  Google Scholar
• 20. Graham T.E., Yang Q., Blüher M., Hammarstedt A., Ciaraldi T.P.,Henry R.R., Wason C.J., Oberbach A., Jansson P.A., Smith U., Kahn B.B.:Retinol-binding protein 4 and insulin resistance in lean, obese, anddiabetic subjects. N. Engl. J. Med., 2006; 354: 2552-2563
  Google Scholar
• 21. Hato T., Tabata M., Oike Y.: The role of angiopoietin-like proteinsin angiogenesis and metabolism. Trends Cardiovasc. Med.,2008; 18: 6-14
  Google Scholar
• 22. Huh J.Y., Panagiotou G., Mougios V., Brinkoetter M., VamviniM.T., Schneider B.E., Mantzoros C.S.: FNDC5 and irisin in humans: I.Predictors of circulating concentrations in serum and plasma andII. mRNA expression and circulating concentrations in response toweight loss and exercise. Metabolism, 2012; 61: 1725-1738
  Google Scholar
• 23. Hutchison S.K., Harrison C., Stepto N., Meyer C., Teede H.J.:Retinol-binding protein 4 and insulin resistance in polycystic ovarysyndrome. Diabetes Care, 2008; 31: 1427-1432
  Google Scholar
• 24. Janke J., Engeli S., Boschmann M., Adams F., Bohnke J., Luft F.C.,Sharma A.M., Jordan J.: Retinol-binding protein 4 in human obesity.Diabetes, 2006; 55: 2805-2810
  Google Scholar
• 25. Kershaw E.E., Flier J.S.: Adipose tissue as an endocrine organ. J.Clin. Endocrinol. Metab., 2004; 89: 2548-2556
  Google Scholar
• 26. Kersten S., Lichtenstein L., Steenbergen E., Mudde K., HendriksH.F.J., Hesselink M.K., Schrauwen P., Müller M.: Caloric restrictionand exercise increase plasma ANGPTL4 levels in humans via elevatedfree fatty acids. Arterioscler. Thromb. Vasc. Biol., 2009; 29: 969-974
  Google Scholar
• 27. Kharitonenkov A., Beals J.M., Micanovic R., Strifler B.A., RathnachalamR., Wroblewski V.J., Li S., Koester A., Ford A.M., Coskun T.,Dunbar J.D., Cheng C.C., Frye C.C., Bumol T.F., Moller D.E.: Rationaldesign of a fibroblast growth factor 21-based clinical candidate,LY2405319. PLoS One, 2013; 8: e58575
  Google Scholar
• 28. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., MicanovicR., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S.,Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J.,Li D.S. i wsp.: FGF-21 as a novel metabolic regulator. J. Clin. Invest.,2005; 115: 1627-1635
  Google Scholar
• 29. Kim H.K., Youn B.S., Shin M.S., Namkoong C., Park K.H., BaikJ.H., Kim J.B., Park J.Y., Lee K.U., Kim Y.B., Kim M.S.: HypothalamicAngptl4/Fiaf is a novel regulator of food intake and body weight.Diabetes, 2010; 59: 2772-2780
  Google Scholar
• 30. Kim I., Kim H.G., Kim H., Kim H.H., Park S.K., Uhm C.S., Lee Z.H.,Koh G.Y.: Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-relatedprotein that prevents endothelialcellapoptosis. Biochem. J., 2000; 346: 603-610
  Google Scholar
• 31. Klöting N., Graham T.E., Berndt J., Kralisch S., Kovacs P., WasonC.J., Fasshauer M., Schön M.R., Stumvoll M., Blüher M., Kahn B.B.:Serum retinol-binding protein is more highly expressed in visceralthan in subcutaneous adipose tissue and is a marker of intra-abdominalfat mass. Cell Metab., 2007; 6: 79-87
  Google Scholar
• 32. Korek E., Krauss H., Piątek J., Chęcińska Z.: Regulacja hormonalnałaknienia. Med. Og. Nauk Zdr., 2013; 19: 211-217
  Google Scholar
• 33. Kos K., Wong S., Tan B., Kerrigan D., Randeva H., Pinkney J.H.,Wilding J.: Human RBP4 adipose tissue expression is gender specificand influenced by leptin. Clin. Endocrinol., 2011; 74: 197-205
  Google Scholar
• 34. Kotnik P., Fischer-Posovszky P., Wabitsch M.: RBP4: a controversialadipokine. Eur. J. Endocrinol., 2011; 165: 703-711
  Google Scholar
• 35. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., OuwensD.M., Eckardt K., Kaufman J.M., Ryden M., Müller S., Hanisch F.G., Ruige J., Arner P., Sell H., Eckel J.: Dipeptidyl peptidase 4 is a noveladipokine potentially linking obesity to the metabolic syndrome.Diabetes, 2011; 60: 1917-1925
  Google Scholar
• 36. Leal Vde O., Mafra D.: Adipokines in obesity. Clin. Chim. Acta,2013; 419: 87-94
  Google Scholar
• 37. Lee D.C., Lee J.W., Im J.A.: Association of serum retinol bindingprotein 4 and insulin resistance in apparently healthy adolescents.Metabolism, 2007; 56: 327-331
  Google Scholar
• 38. Lee J.W., Im J.A., Lee H.R., Shim J.Y., Youn B.S., Lee D.C.: Visceraladiposity is associated with serum retinol binding protein-4 levelsin healthy women. Obesity, 2007; 15: 2225-2232
  Google Scholar
• 39. Lee P., Zhao J.T., Swarbrick M.M., Gracie G., Bova R., GreenfieldJ.R., Freund J., Ho K.K.: High prevalence of brown adipose tissue inadult humans. J. Clin. Endocrinol. Metab., 2011; 96: 2450-2455
  Google Scholar
• 40. Lichtenstein L., Berbée J.F., van Dijk S.J., van Dijk K.W., BensadounA., Kema I.P., Voshol P.J., Müller M., Rensen P.C., Kersten S.: Angptl4upregulates cholesterol synthesis in liver via inhibition of LPL- andHL-dependent hepatic cholesterol uptake. Arterioscler. Thromb.Vasc. Biol., 2007; 27: 2420-2427
  Google Scholar
• 41. Lin C.J., Chu N.F., Hung Y.J., Chang J.B., He C.T., Hsiao F.C., HsiehC.H.: The association of retinol-binding protein 4 with metabolicsyndrome and obesity in adolescents: the effects of gender and sexhormones. Clin. Pediatr., 2013; 52: 16-23
  Google Scholar
• 42. Liu J.J., Wong M.D., Toy W.C., Tan C.S., Liu S., Ng X.W., TavintharanS., Sum C.F., Lim S.C.: Lower circulating irisin is associated withtype 2 diabetes mellitus. J. Diabetes Complications, 2013; 27: 365-369
  Google Scholar
• 43. Makover A., Soprano D.R., Wyatt M.L., Goodman D.S.: Localizationof retinol-binding protein messenger RNA in the rat kidney andin perinephric fat tissue. J. Lipid Res., 1989; 30: 171-180
  Google Scholar
• 44. Mandard S., Zandbergen F., Tan N.S., Escher P., Patsouris D.,Koenig W., Kleemann R., Bakker A., Veenman F., Wahli W., MullerM., Kersten S.: The direct peroxisome proliferator-activated receptortarget fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) ispresent in blood plasma as a truncated protein that is increased byfenofibrate treatment. J. Biol. Chem., 2004; 279: 34411-34420
  Google Scholar
• 45. Mandard S., Zandbergen F., van Straten E., Wahli W., KuipersF., Muller M., Kersten S.: The fasting-induced adipose factor/angiopoietin-likeprotein 4 is physically associated with lipoproteinsand governs plasma lipid levels and adiposity. J. Biol. Chem., 2006;281: 934-944 [46] Martone R.L., Schon E.A., Goodman D.S., Soprano D.R., HerbertJ.: Retinol-binding protein is synthesized in the mammalian eye.Biochem. Biophys. Res. Commun., 1988; 157: 1078-1084 47 Moreno-Navarrete J.M., Ortega F., Serrano M., Guerra E., PardoG., Tinahones F., Ricart W., Fernández-Real J.M.: Irisin is expressedand produced by human muscle and adipose tissue in associationwith obesity and insulin resistance. J. Clin. Endocrinol. Metab., 2013;98: E769-E778 48 Nishimura T., Nakatake Y., Konishi M., Itoh N.: Identification ofa novel FGF, FGF-21, preferentially expressed in the liver. Biochim.Biophys. Acta, 2000; 1492: 203-206 49 Oike Y., Akao M., Yasunaga K., Yamauchi T., Morisada T., Ito Y.,Urano T., Kimura Y., Kubota Y., Maekawa H., Miyamoto T., MiyataK., Matsumoto S., Sakai J., Nakagata N. i wsp.: Angiopoietin-relatedgrowth factor antagonizes obesity and insulin resistance. Nat. Med.,2005; 11: 400-408 50 Ojha S., Birtwistle M., Budge H., Symonds M.E.: Brown adiposetissue: a new human organ? Expert Rev. Endocrinol. Metab., 2013;8: 123-125 51 Pacholczyk M., Ferenc T., Kowalski J.: Zespół metaboliczny. CzęśćI: Definicje i kryteria rozpoznawania zespołu metabolicznego. Epidemiologiaoraz związek z ryzykiem chorób sercowo-naczyniowychi cukrzycy typu 2. Postępy Hig. Med. Dośw., 2008; 62: 530-542 52 Pala L., Rotella C.M.: The role of DPP4 activity in cardiovasculardistricts: in vivo and in vitro evidence. J. Diabetes Res., 2013;2013: 590456 53 Promintzer M., Krebs M., Todoric J., Luger A., Bischof M.G., NowotnyP., Wagner O., Esterbauer H., Anderwald C.: Insulin resistanceis unrelated to circulating retinol binding protein and protein C inhibitor.J. Clin. Endocrinol. Metab., 2007; 92: 4306-4312 54 Rezaee F., Dashty M.: Role of adipose tissue in metabolic systemdisorders – adipose tissue is the initiator of metabolic diseases. J.Diabetes Metab., 2013; S13: 008 55 Rhie Y.J., Choi B.M., Eun S.H., Son C.S., Park S.H., Lee K.H.: Associationof serum retinol binding protein 4 with adiposity and pubertaldevelopment in Korean children and adolescents. J. KoreanMed. Sci., 2011; 26: 797-802 56 Roca-Rivada A., Castelao C., Senin L.L., Landrove M.O., Baltar J.,Belén Crujeiras A., Seoane L.M., Casanueva F.F., Pardo M.: FNDC5/irisin is not only a myokine but also an adipokine. PLoS One, 2013;8: e60563 57 Rocha M., Bañuls C., Bellod L., Rovira-Llopis S., Morillas C., SoláE., Víctor V.M., Hernández-Mijares A.: Association of serum retinolbinding protein 4 with atherogenic dyslipidemia in morbid obesepatients. PLoS One, 2013; 8: e78670 58 Saki F., Karamizadeh Z., Honar N., Moravej H., Ashkani-EsfahaniS., Namvar Shooshtarian M.H.: Association of plasma retinol bindingprotein-4 (RBP4) and sonographic grading of fatty liver in obeseIranian children. Hepat. Mon., 2012; 12: e7103 59 Sanchis-Gomar F., Perez-Quilis C.: Irisinemia: a novel concept tocoin in clinical medicine? Ann. Nutr. Metab., 2013; 63: 60-61 60 Santoro N., Perrone L., Cirillo G., Brienza C., Grandone A., CrestaN., Miraglia del Giudice E.: Variations of retinol binding protein 4levels are not associated with changes in insulin resistance duringpuberty. J. Endocrinol. Invest., 2009; 32: 411-414 61 Sell H., Blüher M., Klöting N., Schlich R., Willems M., Ruppe F.,Knoefel W.T., Dietrich A., Fielding B.A., Arner P., Frayn K.N., Eckel J.:Adipose dipeptidyl peptidase-4 and obesity: correlation with insulinresistance and depot-specific release from adipose tissue in vivo andin vitro. Diabetes Care, 2013; 36: 4083-4090 62 Sesti G., Andreozzi F., Fiorentino T.V., Mannino G.C., SciacquaA., Marini M.A., Perticone F.: High circulating irisin levels are associatedwith insulin resistance and vascular atherosclerosis in a cohortof nondiabetic adult subjects. Acta Diabetol., 2014; 51: 705-713 63 Sivaprasadarao A., Findlay J.B.: Structure-function studies onhuman retinol-binding protein using site-directed mutagenesis.Biochem. J., 1994; 300: 437-442 64 Skurk T., Alberti-Huber C., Herder C., Hauner H.: Relationshipbetween adipocyte size and adipokine expression and secretion. J.Clin. Endocrinol. Metab., 2007; 92: 1023-1033 65 Soprano D.R., Soprano K.J., Goodman D.S.: Retinol-binding proteinmessenger RNA levels in the liver and in extrahepatic tissuesof the rat. J. Lipid Res., 1986; 27: 166-171 66 Soprano D.R., Soprano K.J., Goodman D.S.: Retinol-binding proteinand transthyretin mRNA levels in visceral yolk sac and liverduring fetal development in the rat. Proc. Natl. Acad. Sci. USA, 1986;83: 7330-7334 67 Stefan N., Hennige A.M., Staiger H., Machann J., Schick F.,Schleicher E., Fritsche A., Häring H.U.: High circulating retinolbindingprotein 4 is associated with elevated liver fat but not withtotal, subcutaneous, visceral, or intramyocellular fat in humans.Diabetes Care, 2007; 30: 1173-1178 68 Stengel A., Hofmann T., Goebel-Stengel M., Elbelt U., KobeltP., Klapp B.F.: Circulating levels of irisin in patients with anorexianervosa and different stages of obesity-correlation with body massindex. Peptides, 2013; 39: 125-130 69 Stevens G.A., Singh G.M., Lu Y., Danaei G., Lin J.K., FinucaneM.M., Bahalim A.N., McIntire R.K., Gutierrez H.R., Cowan M., PaciorekC.J., Farzadfar F., Riley L., Ezzati M.: National, regional, andglobal trends in adult overweight and obesity prevalences. Popul.Health Metr., 2012; 10: 22 70 Tabata M., Kadomatsu T., Fukuhara S., Miyata K., Ito Y., Endo M.,Urano T., Zhu H.J., Tsukano H., Tazume H., Kaikita K., Miyashita K.,Iwawaki T., Shimabukuro M., Sakaguchi K. i wsp.: Angiopoietin-likeprotein 2 promotes chronic adipose tissue inflammation and obesityrelatedsystemic insulin resistance. Cell Metab., 2009; 10: 178-188 71 Trayhurn P., Wood I.S.: Adipokines: inflammation and the pleiotropicrole of white adipose tissue. Br. J. Nutr., 2004; 92: 347-355 72 Tsutsumi C., Okuno M., Tannous L., Piantedosi R., Allan M.,Goodman D.S., Blaner W.S.: Retinoids and retinoid-binding proteinexpression in rat adipocytes. J. Biol. Chem., 1992; 267: 1805-1810 73 Turcot V., Tchernof A., Deshaies Y., Pérusse L., Bélisle A., MarceauP., Hould F.S., Lebel S., Vohl M.C.: Comparison of the dipeptidyl peptidase-4gene methylation levels between severely obese subjects withand without the metabolic syndrome. Diabetol. Metab. Syndr., 2013; 5: 4 74 von Eynatten M., Lepper P.M., Liu D., Lang K., Baumann M., NawrothP.P., Bierhaus A., Dugi K.A., Heemann U., Allolio B., Humpert P.M.:Retinol-binding protein 4 is associated with components of the metabolicsyndrome, but not with insulin resistance, in men with type 2diabetes or coronary artery disease. Diabetologia, 2007; 50: 1930-1937 75 Won J.C., Park C.Y, Oh S.W., Park S.W.: Increased plasma levelsof retinol-binding protein 4 with visceral obesity is associated withcardiovascular risk factors. J. Diabetes Invest., 2012; 3: 457-463 76 Woo Y.C., Xu A., Wang Y., Lam K.S.: Fibroblast growth factor 21as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol.,2013; 78: 489-496 77 World Health Organization. Global health risks: mortality andburden of disease attributable to selected major risks. Geneva: WorldHealth Organization, 2009 78 Xu A., Lam M.C., Chan K.W., Wang Y., Zhang J., Hoo R.L., Xu J.Y.,Chen B., Chow W.S., Tso A.W., Lam K.S.: Angiopoietin-like protein 4decreases blood glucose and improves glucose tolerance but induceshyperlipidemia and hepatic steatosis in mice. Proc. Natl. Acad. Sci.USA, 2005; 102: 6086-6091 79 Yang F., Zheng T., Gao Y., Baskota A., Chen T., Ran X., Tian H.:Increased plasma DPP4 activity is an independent predictor of theonset of metabolic syndrome in Chinese over 4 years: result fromthe China National Diabetes and Metabolic Disorders Study. PLoSOne, 2014; 9: e92222 80 Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., ZabolotnyJ.M., Kotani K., Quadro L., Kahn B.B.: Serum retinol binding protein
  Google Scholar

Full text